X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

UPMC Invests in Private Rome Hospital, Plans Expansion of Specialized Services

Yuvraj_pawp by Yuvraj_pawp
21st September 2017
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In a move that will expand advanced cancer services and other specialized treatments to patients in central and southern Italy, UPMC announced today that it is making a strategic investment in Salvator Mundi International Hospital, a well-respected private facility near Rome’s city center. UPMC now owns a 50 percent stake in Salvator Mundi, with the rest held by the current hospital operator, Rome International Hospital Management Srl (RIHM).

“Given UPMC’s long-standing and successful operations in Italy, we are excited about partnering with RIHM to bring more high-quality services to patients who currently are underserved by both private and public health care providers,” said Charles Bogosta, president of UPMC International. “Our strategic investment in Salvator Mundi International ensures that this partnership will promote our mission of giving patients the best possible care close to home.”

Under the leadership of Michele Casciani, who is now chief executive officer of the hospital, Salvator Mundi has successfully revitalized the facility’s operations and finances in recent years, annually drawing about 2,400 admissions and performing about 3,000 surgeries and procedures. UPMC will lead the clinical operations of the 75-bed hospital, including designation of the medical director and chief operating officer.

“Backed by the deep clinical, operational and financial resources of UPMC, we look forward to offering our patients the most advanced medical and surgical oncology services, as well as highly specialized treatments in neurosurgery, interventional radiology and minimally invasive thoracic surgery,” said Casciani. “This partnership creates a model for private health care in Italy and the Mediterranean region, one based on clinical excellence and state-of-the-art technologies and processes.”

Salvator Mundi International is expected to benefit from efficiencies with UPMC’s other Italian operations, including radiotherapy center UPMC San Pietro FBF in Rome, transplant hospital ISMETT in Palermo, the UPMC Institute for Health at the Terme di Chianciano Spa in Chianciano Terme, an outpatient diagnostic and wellness center, and the planned Biomedical Research and Biotechnology Center in Carini. With UPMC’s assistance, Salvator Mundi also aims to achieve Joint Commission International accreditation, enhancing its reputation for high quality, just as UPMC-owned or affiliated facilities have already done in Italy, Ireland and China.

Founded in 1951, Salvator Mundi International was managed by the Sisters of the Divine Savior, an Italian Roman Catholic congregation, until 2012. Operated since that time by RIHM, the hospital has modernized facilities and expanded its base of more than 350 independent physicians, offering a wide range of services in general medicine, surgery, urology, orthopaedics, gynecology, gastroenterology, radiology and other service lines.

Tags: America
Previous Post

New Nymalize Oral Solution 10 mL Unit Dose for the Treatment of Subarachnoid Hemorrhage launched by Arbor Pharma

Next Post

Juno Therapeutics Opens New Headquarters and Research Center

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post

Juno Therapeutics Opens New Headquarters and Research Center

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In